Muscle relaxant

Last updated

A muscle relaxant is a drug that affects skeletal muscle function and decreases the muscle tone. It may be used to alleviate symptoms such as muscle spasms, pain, and hyperreflexia. The term "muscle relaxant" is used to refer to two major therapeutic groups: neuromuscular blockers and spasmolytics. Neuromuscular blockers act by interfering with transmission at the neuromuscular end plate and have no central nervous system (CNS) activity. They are often used during surgical procedures and in intensive care and emergency medicine to cause temporary paralysis. Spasmolytics, also known as "centrally acting" muscle relaxant, are used to alleviate musculoskeletal pain and spasms and to reduce spasticity in a variety of neurological conditions. While both neuromuscular blockers and spasmolytics are often grouped together as muscle relaxant, [1] [2] the term is commonly used to refer to spasmolytics only. [3] [4]

Contents

History

The earliest known use of muscle relaxant drugs was by natives of the Amazon Basin in South America who used poison-tipped arrows that produced death by skeletal muscle paralysis. This was first documented in the 16th century, when European explorers encountered it. This poison, known today as curare, led to some of the earliest scientific studies in pharmacology. Its active ingredient, tubocurarine, as well as many synthetic derivatives, played a significant role in scientific experiments to determine the function of acetylcholine in neuromuscular transmission. [5] By 1943, neuromuscular blocking drugs became established as muscle relaxants in the practice of anesthesia and surgery. [6]

The U.S. Food and Drug Administration (FDA) approved the use of carisoprodol in 1959, metaxalone in August 1962, and cyclobenzaprine in August 1977. [7]

Other skeletal muscle relaxants of that type used around the world come from a number of drug categories and other drugs used primarily for this indication include orphenadrine (anticholinergic), chlorzoxazone, tizanidine (clonidine relative), diazepam, tetrazepam and other benzodiazepines, mephenoxalone, methocarbamol, dantrolene, baclofen. [7] Drugs once but no longer or very rarely used to relax skeletal muscles include meprobamate, barbiturates, methaqualone, glutethimide and the like; some subcategories of opioids have muscle relaxant properties, and some are marketed in combination drugs with skeletal and/or smooth muscle relaxants such as whole opium products, some ketobemidone, piritramide and fentanyl preparations and Equagesic.

Neuromuscular blockers

Detailed view of a neuromuscular junction: Presynaptic terminal Sarcolemma Synaptic vesicle Nicotinic acetylcholine receptor Mitochondrion Synapse diag4.png
Detailed view of a neuromuscular junction:

Muscle relaxation and paralysis can theoretically occur by interrupting function at several sites, including the central nervous system, myelinated somatic nerves, unmyelinated motor nerve terminals, nicotinic acetylcholine receptors, the motor end plate, and the muscle membrane or contractile apparatus. Most neuromuscular blockers function by blocking transmission at the end plate of the neuromuscular junction. Normally, a nerve impulse arrives at the motor nerve terminal, initiating an influx of calcium ions, which causes the exocytosis of synaptic vesicles containing acetylcholine. Acetylcholine then diffuses across the synaptic cleft. It may be hydrolysed by acetylcholine esterase (AchE) or bind to the nicotinic receptors located on the motor end plate. The binding of two acetylcholine molecules results in a conformational change in the receptor that opens the sodium-potassium channel of the nicotinic receptor. This allows Na+
 and Ca2+
 ions to enter the cell and K+
 ions to leave the cell, causing a depolarization of the end plate, resulting in muscle contraction. [8] Following depolarization, the acetylcholine molecules are then removed from the end plate region and enzymatically hydrolysed by acetylcholinesterase. [5]

Normal end plate function can be blocked by two mechanisms. Nondepolarizing agents, such as tubocurarine, block the agonist, acetylcholine, from binding to nicotinic receptors and activating them, thereby preventing depolarization. Alternatively, depolarizing agents, such as succinylcholine, are nicotinic receptor agonists which mimic Ach, block muscle contraction by depolarizing to such an extent that it desensitizes the receptor and it can no longer initiate an action potential and cause muscle contraction. [5] Both of these classes of neuromuscular blocking drugs are structurally similar to acetylcholine, the endogenous ligand, in many cases containing two acetylcholine molecules linked end-to-end by a rigid carbon ring system, as in pancuronium (a nondepolarizing agent). [5]

Chemical diagram of pancuronium, with red lines indicating the two acetylcholine "molecules" in the structure Pancuronium acetylcholine-highlighted.png
Chemical diagram of pancuronium, with red lines indicating the two acetylcholine "molecules" in the structure

Spasmolytics

A view of the spinal cord and skeletal muscle showing the action of various muscle relaxants - black lines ending in arrowheads represent chemicals or actions that enhance the target of the lines, blue lines ending in squares represent chemicals or actions that inhibit the target of the line Spasticity2.svg
A view of the spinal cord and skeletal muscle showing the action of various muscle relaxants – black lines ending in arrowheads represent chemicals or actions that enhance the target of the lines, blue lines ending in squares represent chemicals or actions that inhibit the target of the line

The generation of the neuronal signals in motor neurons that cause muscle contractions is dependent on the balance of synaptic excitation and inhibition the motor neuron receives. Spasmolytic agents generally work by either enhancing the level of inhibition or reducing the level of excitation. Inhibition is enhanced by mimicking or enhancing the actions of endogenous inhibitory substances, such as GABA.

Terminology

Because they may act at the level of the cortex, brain stem, or spinal cord, or all three areas, they have traditionally been referred to as "centrally acting" muscle relaxants. However, it is now known not every agent in this class has CNS activity (e.g., dantrolene), so this name is inaccurate. [5]

Most sources still use the term "centrally acting muscle relaxant". According to MeSH, dantrolene is usually classified as a centrally acting muscle relaxant. [9] The World Health Organization, in its ATC, uses the term "centrally acting agents", [10] but adds a distinct category of "directly acting agents", for dantrolene. [11] Use of this terminology dates back to at least 1973. [12]

The term "spasmolytic" is also considered a synonym for antispasmodic. [13]

Clinical use

Spasmolytics such as carisoprodol, cyclobenzaprine, metaxalone, and methocarbamol are commonly prescribed for low back pain or neck pain, fibromyalgia, tension headaches and myofascial pain syndrome. [14] However, they are not recommended as first-line agents; in acute low back pain, they are not more effective than paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs), [15] [16] and in fibromyalgia they are not more effective than antidepressants. [14] Nevertheless, some (low-quality) evidence suggests muscle relaxants can add benefit to treatment with NSAIDs. [17] In general, no high-quality evidence supports their use. [14] No drug has been shown to be better than another, and all of them have adverse effects, particularly dizziness and drowsiness. [14] [16] Concerns about possible abuse and interaction with other drugs, especially if increased sedation is a risk, further limit their use. [14] A muscle relaxant is chosen based on its adverse-effect profile, tolerability, and cost. [18]

Muscle relaxants (according to one study) were not advised for orthopedic conditions, but rather for neurological conditions such as spasticity in cerebral palsy and multiple sclerosis. [14] Dantrolene, although thought of primarily as a peripherally acting agent, is associated with CNS effects, whereas baclofen activity is strictly associated with the CNS.

Muscle relaxants are thought to be useful in painful disorders based on the theory that pain induces spasm and spasm causes pain. However, considerable evidence contradicts this theory. [17]

In general, muscle relaxants are not approved by FDA for long-term use. However, rheumatologists often prescribe cyclobenzaprine nightly on a daily basis to increase stage 4 sleep. By increasing this sleep stage, patients feel more refreshed in the morning. Improving sleep is also beneficial for patients who have fibromyalgia. [19]

Muscle relaxants such as tizanidine are prescribed in the treatment of tension headaches. [20]

Diazepam and carisoprodol are not recommended for older adults, pregnant women, or people who have depression or for those with a history of drug or alcohol addiction. [21]

Mechanism

Because of the enhancement of inhibition in the CNS, most spasmolytic agents have the side effects of sedation and drowsiness and may cause dependence with long-term use. Several of these agents also have abuse potential, and their prescription is strictly controlled. [22] [23] [24]

The benzodiazepines, such as diazepam, interact with the GABAA receptor in the central nervous system. While it can be used in patients with muscle spasm of almost any origin, it produces sedation in most individuals at the doses required to reduce muscle tone. [5]

Baclofen is considered to be at least as effective as diazepam in reducing spasticity, and causes much less sedation. It acts as a GABA agonist at GABAB receptors in the brain and spinal cord, resulting in hyperpolarization of neurons expressing this receptor, most likely due to increased potassium ion conductance. Baclofen also inhibits neural function presynaptically, by reducing calcium ion influx, and thereby reducing the release of excitatory neurotransmitters in both the brain and spinal cord. It may also reduce pain in patients by inhibiting the release of substance P in the spinal cord, as well. [5] [25]

Clonidine and other imidazoline compounds have also been shown to reduce muscle spasms by their central nervous system activity. Tizanidine is perhaps the most thoroughly studied clonidine analog, and is an agonist at α2-adrenergic receptors, but reduces spasticity at doses that result in significantly less hypotension than clonidine. [26] Neurophysiologic studies show that it depresses excitatory feedback from muscles that would normally increase muscle tone, therefore minimizing spasticity. [27] [28] Furthermore, several clinical trials indicate that tizanidine has a similar efficacy to other spasmolytic agents, such as diazepam and baclofen, with a different spectrum of adverse effects. [29]

The hydantoin derivative dantrolene is a spasmolytic agent with a unique mechanism of action outside of the CNS. It reduces skeletal muscle strength by inhibiting the excitation-contraction coupling in the muscle fiber. In normal muscle contraction, calcium is released from the sarcoplasmic reticulum through the ryanodine receptor channel, which causes the tension-generating interaction of actin and myosin. Dantrolene interferes with the release of calcium by binding to the ryanodine receptor and blocking the endogenous ligand ryanodine by competitive inhibition. Muscle that contracts more rapidly is more sensitive to dantrolene than muscle that contracts slowly, although cardiac muscle and smooth muscle are depressed only slightly, most likely because the release of calcium by their sarcoplasmic reticulum involves a slightly different process. Major adverse effects of dantrolene include general muscle weakness, sedation, and occasionally hepatitis. [5]

Other common spasmolytic agents include: methocarbamol, carisoprodol, chlorzoxazone, cyclobenzaprine, gabapentin, metaxalone, and orphenadrine.

Thiocolchicoside is a muscle relaxant with anti-inflammatory and analgesic effects and an unknown mechanism of action. [30] [31] [32] [33] It acts as a competitive antagonist at GABAA and glycine receptors with similar potencies, as well as at nicotinic acetylcholine receptors, albeit to a much lesser extent. [34] [35] It has powerful proconvulsant activity and should not be used in seizure-prone individuals. [36] [37] [38]

Side effects

Patients most commonly report sedation as the main adverse effect of muscle relaxants. Usually, people become less alert when they are under the effects of these drugs. People are normally advised not to drive vehicles or operate heavy machinery while under muscle relaxants' effects.

Cyclobenzaprine produces confusion and lethargy, as well as anticholinergic side effects. When taken in excess or in combination with other substances, it may also be toxic. While the body adjusts to this medication, it is possible for patients to experience dry mouth, fatigue, lightheadedness, constipation or blurred vision. Some serious but unlikely side effects may be experienced, including mental or mood changes, possible confusion and hallucinations, and difficulty urinating. In a very few cases, very serious but rare side effects may be experienced: irregular heartbeat, yellowing of eyes or skin, fainting, abdominal pain including stomach ache, nausea or vomiting, lack of appetite, seizures, dark urine or loss of coordination. [39]

Patients taking carisoprodol for a prolonged time have reported dependence, withdrawal and abuse, although most of these cases were reported by patients with addiction history. These effects were also reported by patients who took it in combination with other drugs with abuse potential, and in fewer cases, reports of carisoprodol-associated abuse appeared when used without other drugs with abuse potential. [40]

Common side effects eventually caused by metaxalone include dizziness, headache, drowsiness, nausea, irritability, nervousness, upset stomach and vomiting. Severe side effects may be experienced when consuming metaxalone, such as severe allergic reactions (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), chills, fever, and sore throat, may require medical attention. Other severe side effects include unusual or severe tiredness or weakness, as well as yellowing of the skin or the eyes. [41] When baclofen is administered intrathecally, it may cause CNS depression accompanied with cardiovascular collapse and respiratory failure. Tizanidine may lower blood pressure. This effect can be controlled by administering a low dose at the beginning and increasing it gradually. [42]

See also

Related Research Articles

<span class="mw-page-title-main">Suxamethonium chloride</span> Chemical compound

Suxamethonium chloride, also known as suxamethonium or succinylcholine, or simply sux in medical abbreviation, is a medication used to cause short-term paralysis as part of general anesthesia. This is done to help with tracheal intubation or electroconvulsive therapy. It is administered by injection, either into a vein or into a muscle. When used in a vein, onset of action is generally within one minute and effects last for up to 10 minutes.

<span class="mw-page-title-main">Pancuronium bromide</span> Aminosteroid muscle relaxant

Pancuronium is an aminosteroid muscle relaxant with various medical uses. It is used in euthanasia and is used in some states as the second of three drugs administered during lethal injections in the United States.

An antispasmodic is a pharmaceutical drug or other agent that suppresses muscle spasms.

Anticholinergics are substances that block the action of the acetylcholine (ACh) neurotransmitter at synapses in the central and peripheral nervous system.

<span class="mw-page-title-main">Dantrolene</span> Chemical compound

Dantrolene sodium, sold under the brand name Dantrium among others, is a postsynaptic muscle relaxant that lessens excitation-contraction coupling in muscle cells. It achieves this by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors. It is the primary drug used for the treatment and prevention of malignant hyperthermia, a rare, life-threatening disorder triggered by general anesthesia or drugs. It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (e.g. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis), and poisoning by 2,4-dinitrophenol or by the related compounds dinoseb and dinoterb.

ATC code M03Muscle relaxants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup M03 is part of the anatomical group M Musculo-skeletal system.

<span class="mw-page-title-main">Cyclobenzaprine</span> Muscle relaxant medication

Cyclobenzaprine, sold under several brand names including, historically, Flexeril, is a muscle relaxer used for muscle spasms from musculoskeletal conditions of sudden onset. It is not useful in cerebral palsy. It is taken by mouth.

<span class="mw-page-title-main">Methocarbamol</span> Medication for musculoskeletal pain

Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain. It may be used together with rest, physical therapy, and pain medication. It is less preferred in low back pain. It has limited use for rheumatoid arthritis and cerebral palsy. Effects generally begin within half an hour. It is taken by mouth or injection into a vein.

<span class="mw-page-title-main">Tubocurarine chloride</span> Obsolete muscle relaxant

Tubocurarine is a toxic benzylisoquinoline alkaloid historically known for its use as an arrow poison. In the mid-1900s, it was used in conjunction with an anesthetic to provide skeletal muscle relaxation during surgery or mechanical ventilation. Safer alternatives, such as cisatracurium and rocuronium, have largely replaced it as an adjunct for clinical anesthesia and it is now rarely used.

<span class="mw-page-title-main">Neuromuscular-blocking drug</span> Type of paralyzing anesthetic including lepto- and pachycurares

Neuromuscular-blocking drugs, or Neuromuscular blocking agents (NMBAs), block transmission at the neuromuscular junction, causing paralysis of the affected skeletal muscles. This is accomplished via their action on the post-synaptic acetylcholine (Nm) receptors.

<span class="mw-page-title-main">Tizanidine</span> Muscle relaxant medication

Tizanidine, sold under the brand name Zanaflex among others, is an alpha-2 (α2) adrenergic receptor agonist, similar to clonidine, that is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Effectiveness appears similar to baclofen or diazepam. It is taken by mouth.

A cholinergic crisis is an over-stimulation at a neuromuscular junction due to an excess of acetylcholine (ACh), as a result of the inactivity of the AChE enzyme, which normally breaks down acetylcholine.

Decamethonium (Syncurine) is a depolarizing muscle relaxant or neuromuscular blocking agent, and is used in anesthesia to induce paralysis.

<span class="mw-page-title-main">Mivacurium chloride</span> Drug used in a hospital setting

Mivacurium chloride is a short-duration non-depolarizing neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

<span class="mw-page-title-main">Doxacurium chloride</span> Pharmaceutical drug

Doxacurium chloride is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. Unlike a number of other related skeletal muscle relaxants, it is rarely used adjunctively to facilitate endotracheal intubation.

<span class="mw-page-title-main">Chlorzoxazone</span> Muscle relaxant

Chlorzoxazone (INN) is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It can also be administered for acute pain in general and for tension headache. It acts on the spinal cord by depressing reflexes. It is sold under the brand names Lorzone, Paraflex and Muscol and in combination form as Parafon Forte, a combination of chlorzoxazone and acetaminophen (paracetamol). Possible side effects include dizziness, lightheadedness, malaise, nausea, vomiting, and liver dysfunction. When used with acetaminophen it has added risk of hepatotoxicity.

<span class="mw-page-title-main">Thiocolchicoside</span> Chemical compound

Thiocolchicoside is a muscle relaxant with anti-inflammatory and analgesic effects. Its mechanism of action is unknown, but it is believed to be act via antagonism of nicotinic acetylcholine receptors (nAchRs). However, it also appears to be a competitive antagonist of GABAA and glycine receptors. As such, it has powerful convulsant activity and should not be used in seizure-prone individuals.

An analgesic adjuvant is a medication that is typically used for indications other than pain control but provides control of pain (analgesia) in some painful diseases. This is often part of multimodal analgesia, where one of the intentions is to minimize the need for opioids.

<span class="mw-page-title-main">Cholinergic blocking drug</span> Drug that block acetylcholine in synapses of cholinergic nervous system

Cholinergic blocking drugs are a group of drugs that block the action of acetylcholine (ACh), a neurotransmitter, in synapses of the cholinergic nervous system. They block acetylcholine from binding to cholinergic receptors, namely the nicotinic and muscarinic receptors.

<span class="mw-page-title-main">Neuromuscular drug</span>

Neuromuscular drugs are chemical agents that are used to alter the transmission of nerve impulses to muscles, causing effects such as temporary paralysis of targeted skeletal muscles. Most neuromuscular drugs are available as quaternary ammonium compounds which are derived from acetylcholine (ACh). This allows neuromuscular drugs to act on multiple sites at neuromuscular junctions, mainly as antagonists or agonists of post-junctional nicotinic receptors. Neuromuscular drugs are classified into four main groups, depolarizing neuromuscular blockers, non-depolarizing neuromuscular blockers, acetylcholinesterase inhibitors, and butyrylcholinesterase inhibitors.

References

  1. ↑ "Definition of Muscle relaxant Archived 2013-10-16 at the Wayback Machine ." MedicineNet.com. (c) 1996–2007. Retrieved on September 19, 2007.
  2. ↑ "muscle relaxant Archived 2013-10-06 at the Wayback Machine ." mediLexicon Archived 2013-10-06 at the Wayback Machine . (c) 2007. Retrieved on September 19, 2007.
  3. ↑ "Muscle relaxants." WebMD. Last Updated: February 15, 2006. Retrieved on September 19, 2007.
  4. ↑ "Skeletal Muscle Relaxant (Oral Route, Parenteral Route)." Mayo Clinic. Last Updated: April 1, 2007. Retrieved on September 19, 2007.
  5. 1 2 3 4 5 6 7 8 Miller, R.D. (1998). "Skeletal Muscle Relaxants" . In Katzung, B.G. (ed.). Basic & Clinical Pharmacology (7th ed.). Appleton & Lange. pp.  434–449. ISBN   0-8385-0565-1.
  6. ↑ Bowman WC (January 2006). "Neuromuscular block". Br. J. Pharmacol. 147 (Suppl 1): S277–86. doi:10.1038/sj.bjp.0706404. PMC   1760749 . PMID   16402115.
  7. 1 2 "Brief History" . Retrieved 2010-07-09.
  8. ↑ Craig, C.R.; Stitzel, R.E. (2003). Modern Pharmacology with clinical applications . Lippincott Williams & Wilkins. p.  339. ISBN   0-7817-3762-1.
  9. ↑ Dantrolene at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  10. ↑ "M03B Muscle Relaxants, Centrally acting agents". ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.
  11. ↑ "M03CA01 Dantrolene". ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.
  12. ↑ Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JE, Halliday RP (June 1973). "Dantrolene, a direct acting skeletal muscle relaxant". J Pharm Sci. 62 (6): 948–51. doi:10.1002/jps.2600620619. PMID   4712630.
  13. ↑ "Dorlands Medical Dictionary:antispasmodic". Archived from the original on 2009-10-01.
  14. 1 2 3 4 5 6 See S, Ginzburg R (2008). "Choosing a skeletal muscle relaxant". Am Fam Physician. 78 (3): 365–370. ISSN   0002-838X. PMID   18711953.
  15. ↑ Chou R, Qaseem A, Snow V, Casey D, Cross JT, Shekelle P, Owens DK (October 2007). "Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society". Ann. Intern. Med. 147 (7): 478–91. doi: 10.7326/0003-4819-147-7-200710020-00006 . PMID   17909209.
  16. 1 2 van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM (2003). "Muscle relaxants for non-specific low back pain". Cochrane Database Syst Rev. 2017 (2): CD004252. doi:10.1002/14651858.CD004252. PMC   6464310 . PMID   12804507.
  17. 1 2 Beebe FA, Barkin RL, Barkin S (2005). "A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions". Am J Ther. 12 (2): 151–71. doi:10.1097/01.mjt.0000134786.50087.d8. PMID   15767833. S2CID   24901082.
  18. ↑ See S, Ginzburg R (February 2008). "Skeletal muscle relaxants". Pharmacotherapy. 28 (2): 207–13. doi:10.1592/phco.28.2.207. PMID   18225966. S2CID   43152771.
  19. ↑ "When Are Muscle Relaxers Prescribed For Arthritis Patients?". Archived from the original on 2010-12-05. Retrieved 2010-07-09.
  20. ↑ MedlinePlus Encyclopedia : Tension Headache
  21. ↑ "Muscle Relaxants" . Retrieved 2010-07-09.
  22. ↑ Rang, H.P.; Dale, M.M. (1991). "Drugs Used in Treating Motor Disorders". Pharmacology (2nd ed.). Churchill Livingston. pp. 684–705. ISBN   0-443-04483-X.
  23. ↑ Standaert, D.G.; Young, A.B. (2001). "Treatment Of Central Nervous System Degerative Disorders". In Goodman, L.S.; Hardman, J.G.; Limbird, L.E.; Gilman, A.G. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10th ed.). McGraw Hill. pp. 550–568. ISBN   0-07-112432-2.
  24. ↑ Charney, D.S.; Mihic, J.; Harris, R.A. (2001). "Hypnotics and Sedatives". Goodman & Gilman's . pp. 399–427.
  25. ↑ Cazalets JR, Bertrand S, Sqalli-Houssaini Y, Clarac F (November 1998). "GABAergic control of spinal locomotor networks in the neonatal rat". Ann. N. Y. Acad. Sci. 860 (1): 168–80. Bibcode:1998NYASA.860..168C. doi:10.1111/j.1749-6632.1998.tb09047.x. PMID   9928310. S2CID   33042651.
  26. ↑ Young, R.R., ed. (1994). "Symposium: Role of tizanidine in the treatment of spasticity". Neurology. 44 (Suppl 9): S1-80. PMID   7970005.
  27. ↑ Bras H, Jankowska E, Noga B, Skoog B (1990). "Comparison of Effects of Various Types of NA and 5-HT Agonists on Transmission from Group II Muscle Afferents in the Cat". Eur. J. Neurosci. 2 (12): 1029–1039. doi:10.1111/j.1460-9568.1990.tb00015.x. PMID   12106064. S2CID   13552923.
  28. ↑ Jankowska E, Hammar I, Chojnicka B, Hedén CH (February 2000). "Effects of monoamines on interneurons in four spinal reflex pathways from group I and/or group II muscle afferents". Eur. J. Neurosci. 12 (2): 701–14. doi:10.1046/j.1460-9568.2000.00955.x. PMID   10712650. S2CID   21546330.
  29. ↑ Young RR, Wiegner AW (June 1987). "Spasticity". Clin. Orthop. Relat. Res. (219): 50–62. PMID   3581584.
  30. ↑ Tüzün F, Unalan H, Oner N, Ozgüzel H, Kirazli Y, Içağasioğlu A, Kuran B, Tüzün S, Başar G (September 2003). "Multicenter, randomized, double-blinded, placebo-controlled trial of thiocolchicoside in acute low back pain". Joint, Bone, Spine. 70 (5): 356–61. doi:10.1016/S1297-319X(03)00075-7. PMID   14563464.
  31. ↑ Ketenci A, Basat H, Esmaeilzadeh S (July 2009). "The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study". Agri. 21 (3): 95–103. PMID   19780000.
  32. ↑ Soonawalla DF, Joshi N (May 2008). "Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm". Journal of the Indian Medical Association. 106 (5): 331–5. PMID   18839644.
  33. ↑ Ketenci A, Ozcan E, Karamursel S (July 2005). "Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain". International Journal of Clinical Practice. 59 (7): 764–70. doi: 10.1111/j.1742-1241.2004.00454.x . PMID   15963201. S2CID   20671452.
  34. ↑ Carta M, Murru L, Botta P, Talani G, Sechi G, De Riu P, Sanna E, Biggio G (September 2006). "The muscle relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system". Neuropharmacology. 51 (4): 805–15. doi:10.1016/j.neuropharm.2006.05.023. PMID   16806306. S2CID   11390033.
  35. ↑ Mascia MP, Bachis E, Obili N, Maciocco E, Cocco GA, Sechi GP, Biggio G (March 2007). "Thiocolchicoside inhibits the activity of various subtypes of recombinant GABA(A) receptors expressed in Xenopus laevis oocytes". European Journal of Pharmacology. 558 (1–3): 37–42. doi:10.1016/j.ejphar.2006.11.076. PMID   17234181.
  36. ↑ De Riu PL, Rosati G, Sotgiu S, Sechi G (August 2001). "Epileptic seizures after treatment with thiocolchicoside". Epilepsia. 42 (8): 1084–6. doi:10.1046/j.1528-1157.2001.0420081084.x. PMID   11554898. S2CID   24017279.
  37. ↑ Giavina-Bianchi P, Giavina-Bianchi M, Tanno LK, Ensina LF, Motta AA, Kalil J (June 2009). "Epileptic seizure after treatment with thiocolchicoside". Therapeutics and Clinical Risk Management. 5 (3): 635–7. doi: 10.2147/tcrm.s4823 . PMC   2731019 . PMID   19707540.
  38. ↑ Sechi G, De Riu P, Mameli O, Deiana GA, Cocco GA, Rosati G (October 2003). "Focal and secondarily generalised convulsive status epilepticus induced by thiocolchicoside in the rat". Seizure. 12 (7): 508–15. doi: 10.1016/S1059-1311(03)00053-0 . PMID   12967581. S2CID   14308541.
  39. ↑ "Cyclobenzaprine-Oral" . Retrieved 2010-07-09.
  40. ↑ "Carisoprodolx" . Retrieved 2010-07-09.
  41. ↑ "Side Effects of Metaxalone – for the Consumer" . Retrieved 2010-07-09.
  42. ↑ "Precautions". Encyclopedia of Surgery. Retrieved 2010-07-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.